TIF and the Angel Mama Foundation visit Reforgene to advance global access for thalassemia gene medicine
On March 19, 2026, a delegation of the Thalassaemia International Federation (TIF) and the Beijing Angel Mama Charity Foundation visited Guangzhou Reforgene Medicine Co., Ltd. for in-depth exchanges and discussions on topics including innovative R&D of thalassemia gene editing treatment, global strategic cooperation, patient rights protection and technology accessibility. The visit brought together internationally authoritative experts and domestic public welfare forces, and was not only high recognition of Reforgene's leading strength in thalassemia gene editing treatment, but also built an important cooperation bridge for the coordinated development of global thalassemia prevention and treatment.
The visiting delegation was authoritative and professional, composed of authoritative scholars and clinical experts in thalassemia from Italy, Cyprus, Greece and Indonesia on the TIF Medical Advisory Committee, including Piga Antonio Giulio, Dimitrios Farmakis, Evangelia Yannaki and Ludi Dhyani Rahmartani, as well as Qiu Lili, Director of the Beijing Angel Mama Charity Foundation, Mao Yutao, Deputy Secretary-General, and Xia Yu, Head of the Cooperation Development Department. Dr. Liang Junbin, CEO of Reforgene, led the team to receive the delegation and host the discussion.
During the discussion, Reforgene gave a detailed introduction to the company's innovative strategic layout for gene editing medicines, the clinical research progress of its thalassemia product RM001, and other key technological achievements. Combining global thalassemia prevention and treatment practices and the frontier of gene therapy, TIF experts conducted in-depth discussions with the Reforgene team on core topics such as technical routes, clinical efficacy, international standards and full-cycle patient protection. The two sides reached a high degree of consensus on directions including technology sharing, experience exchange and global promotion.
After the discussion, the delegation visited Reforgene's R&D laboratories and GMP-standard production workshops to systematically understand the R&D progress of the thalassemia gene editing medicine pipeline and the full-chain quality control system. Reforgene's rigorous R&D processes and world-class production quality control standards received unanimous praise and high recognition from the delegation.
As the only innovative enterprise in the world to have achieved cures for both alpha- and beta-thalassemia, Reforgene has established a significant leading advantage in the thalassemia gene medicine field. Taking this exchange as an opportunity, the company will further absorb advanced international experience, accelerate technological innovation and the application of drug achievements, deepen global multi-party cooperation, promote thalassemia gene medicines with excellent clinical efficacy to the world, and provide more patients with cure and new life.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.